CD4 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting of the downstream JAK-STAT pathway by ruxolitinib [119], a JAK1/2 inhibitor, recovered MHC-II expression and increased the proliferation of CD4+ cells against CML-LSC.